Posted by Michael Wonder on 05 Oct 2020
Radiopharmaceutical Lutathera now reimbursed in Quebec for cancer patients with advanced gastro-enteropancreatic neuroendocrine tumours
1 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical indicated in the treatment of GEP-NETs in Canada.
Advanced Accelerator Applications is pleased to announce that eligible Quebec patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs) – a life-threatening form of cancer affecting the neuroendocrine cells of the pancreas and gastrointestinal tract - now have access to the innovative new radiopharmaceutical therapy, Lutathera (lutetium (177Lu) oxodotreotide).
Quebec joins Nova Scotia to provide access to Lutathera for eligible patients with GEP-NETs.
